Insights from EU Coronary IVL Use & Overview of DISRUPT CAD III Study (5 of 6)

Works at The Christ Hospital Heart and Vascular Center/The Lindner Research Center, Cincinnati,... Works at The Christ Hospital Heart and Vascular Center/The Lindner Research Center, Cincinnati, OH, USA. Features in 9 videos on Wondr Medical. Dean Kereiakes generally speaks on Peripheral Vascular Disease (PVD), Coronary Interventions, Impella, Shockwave Lithotripsy (Coronary), and Transcatheter Aortic Valve Implantation (TAVR / TAVI). Read more Show less

Consultant Interventional Cardiologist and Revascularisation Group Chair at Royal Brompton... Consultant Interventional Cardiologist and Revascularisation Group Chair at Royal Brompton Hospital, London. His clinical focus is on use of intravascular imaging in complex PCI , CTO and cardiogenic shock. His clinical research interests focus on optical coherence tomography, calcific coronary disease and percutaneous ventricular support. Dr Hill was global co-chief investigator for the DISRUPT CAD III study and has served as UK principal investigator for multiple interventional trials. He has served as a CTO and complex PCI proctor on a global basis and works closely with OPTIMA to focus on the development of OPTIMAL PCI. He is the founding co-director of the Complete Revascularisation (CoRe) meetings held every year in London. Read more Show less

Features in 7 videos on Wondr Medical. Peter Soukas generally speaks on Coronary Optical... Features in 7 videos on Wondr Medical. Peter Soukas generally speaks on Coronary Optical Coherence Tomography (OCT), Atherectomy, Peripheral Vascular Disease (PVD), Coronary Interventions, and Impella. Read more Show less

Gregg W. Stone, MD, FACC, MSCAI is an interventional cardiologist and Director of Academic... Gregg W. Stone, MD, FACC, MSCAI is an interventional cardiologist and Director of Academic Affairs for the Mount Sinai Heart Health System and Professor of Medicine (Cardiology) and Professor of Population Health Sciences and Policy at the Icahn School of Medicine at Mount Sinai in New York, NY. Dr. Stone has served as the national or international principal investigator for more than 120 national and international multicenter randomized trials (many of which have led to new device approval or indications in the US), has authored more than 2000 manuscripts and abstracts published in the peer-reviewed literature, and has delivered thousands of invited lectures around the world. With a 2018 H-factor of 152, Dr. Stone was recently listed in Nature Medicine as one of the most prolific authors in science. Dr. Stone's areas of expertise include interventional therapies of acute coronary syndromes, myocardial infarction and cardiogenic shock; drug-eluting stents and bioresorbable scaffolds; left main and complex coronary artery disease intervention; antiplatelet and antithrombotic pharmacotherapies; transcatheter valve repair and replacement; interventional hypertension and heart failure therapies; left atrial appendage closure; intravascular imaging (IVUS, OCT and NIRS); vulnerable plaque diagnosis and treatment; adjunctive interventional devices including atherectomy, distal embolic protection, thrombectomy, covered stents, chronic total occlusion devices, and brachytherapy; saphenous vein graft therapies; contrast nephropathy; clinical trial design; and regulatory issues. Dr. Stone is the director of TCT, the world's largest symposium devoted to interventional cardiology and vascular medicine. Dr. Stone founded the annual National Interventional Cardiology Fellow's Course and Transcatheter Valve Therapies TVT), the Chronic Total Occlusion (CTO) Summit, and co-directs multiple other meetings in the US, China, Russia, Europe, S. Korea and elsewhere. Read more Show less